论文部分内容阅读
目的:研究PIK3CA基因在浆液性卵巢癌中的拷贝数变异(CNV)情况,探讨PIK3CA参与卵巢癌发生发展的可能机制及其预后。方法:从癌症基因组图谱(TCGA)数据库收集浆液性卵巢癌数据(591例患者/603例样本)及其临床资料,包括CNV、m RNA表达和蛋白表达数据。分析PIK3CA基因拷贝数变异与基因表达和预后的相关及其共表达蛋白。对PIK3CA和其相关共表达蛋白进行基因集富集分析。结果:PIK3CA基因在27.7%的卵巢癌患者中发生拷贝数扩增,且与其m RNA表达和蛋白表达呈显著正相关,预后显著较好(OS:P=0.0469;PFS:P=0.0241)。PIK3CA基因拷贝数扩增和表达升高富集了胰岛素信号通路、Erb B通路、m TOR信号通路等基因集。结论:PIK3CA基因拷贝数扩增在高级别浆液性卵巢癌中是一种预后较好因素,通过不同信号通路在肿瘤进展中发挥重要作用,可作为判断预后的标记物。
Objective: To investigate the copy number variation (CNV) of PIK3CA gene in serous ovarian cancer and to explore the possible mechanism and prognosis of PIK3CA in ovarian cancer. METHODS: Serous ovarian cancer data (591 patients / 603 samples) and their clinical data, including CNV, m RNA expression and protein expression data, were collected from the Cancer Genome Atlas (TCGA) database. To analyze the correlation between PIK3CA gene copy number variation and gene expression and prognosis and its co-expression protein. Gene enrichment analysis of PIK3CA and its related co-expressed proteins. Results: The PIK3CA gene was amplified in 27.7% of ovarian cancer patients. The expression of PIK3CA gene was positively correlated with its mRNA expression and protein expression. The prognosis was significantly better (OS: P = 0.0469; PFS: P = 0.0241). PIK3CA gene copy number amplification and expression increased enrich the insulin signaling pathway, Erb B pathway, m TOR signaling pathway and other gene sets. Conclusion: Amplification of PIK3CA gene copy number is a good prognostic factor in high-grade serous ovarian cancer. It plays an important role in tumor progression through different signaling pathways and can be used as a marker for prognosis.